Chugai Pharmaceutical Co., Ltd. (OTCMKTS:CHGCY - Get Free Report) saw a large growth in short interest in the month of December. As of December 31st, there was short interest totalling 36,800 shares, a growth of 1,500.0% from the December 15th total of 2,300 shares. Based on an average daily trading volume, of 214,500 shares, the short-interest ratio is currently 0.2 days.
Chugai Pharmaceutical Trading Down 0.1 %
Shares of OTCMKTS:CHGCY traded down $0.02 during trading on Monday, hitting $21.08. 120,853 shares of the company's stock traded hands, compared to its average volume of 321,365. The company has a 50-day moving average price of $22.00 and a 200-day moving average price of $22.27. Chugai Pharmaceutical has a 52 week low of $14.52 and a 52 week high of $26.00. The company has a market cap of $69.37 billion, a price-to-earnings ratio of 27.03 and a beta of 0.81.
About Chugai Pharmaceutical
(
Get Free Report)
Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.
See Also
Before you consider Chugai Pharmaceutical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Chugai Pharmaceutical wasn't on the list.
While Chugai Pharmaceutical currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
